|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||243.82 - 245.95|
|52-week range||243.82 - 245.95|
|Beta (5Y monthly)||1.04|
|PE ratio (TTM)||11.19|
|Earnings date||27 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BURLINGTON, N.C., May 18, 2022--Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue. LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. The test is available for use in both clinical trials and for the care and treatment of patien
BURLINGTON, N.C., May 18, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.
BURLINGTON, N.C., May 17, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 at 2:45 p.m. ET.